Strain differences in tamoxifen sensitivity of Sprague-Dawley and Fischer 344 rats

Jason A. Bailey, Kenneth Nephew

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Why some women are at increased risk for the development of endometrial carcinoma while taking the antiestrogen tamoxifen (Tam) for breast cancer treatment or prevention is unknown. Various strains of rodents display differences in sensitivity to compounds with estrogenic activity, but whether differences in Tam sensitivity exist in rodent strains has not been investigated. In the present study, we investigated whether rat strain differences in reproductive tract sensitivity to Tam and estrogen exist between Fischer 344 (F344) and Sprague Dawley (SD) rats. Immature (21-23 day; n=6/group), ovariectomized F344 and SD rats were treated with vehicle (control), 17 β-estradiol (E2) [1 × 10-6 to 1.0 μg/kg body weight (BW)] or 4-OH tamoxifen (4-OHT) (1 × 10-4 to 10 mg/kg BW) for 2 days and then sacrificed on day 3. Reproductive tracts were collected, weighed, and examined for changes in histomorphology and expression of ERα and nuclear receptor co-regulators (SRC1, p300, CARM1, GRIP1, SPA, REA and Uba3). Treatment with E2 (1 × 10-5 μg/kg BW) increased (p<0.05) uterine epithelial cell height in F344 but not SD rats, demonstrating increased sensitivity of the F344 strain to E2. Conversely, treatment with 1 × 10-3 mg/kg BW 4-OHT increased (p<0.05) uterine weight and epithelial cell height in SD but not F344 rats, demonstrating that the SD strain is more sensitive to the antiestrogen. Northern and Western blot and immunohistochemical analysis revealed that ERα expression levels in the SD and F344 uterus were not different. Expression of receptor co-regulators was higher in the uterus compared to the vagina regardless of strain and higher CARM1 expression was seen in SD uterus compared to F344 rats. Understanding differences in Tam sensitivity may help us to better understand why some women develop endometrial cancer while taking Tam and be beneficial in treatment decisions for breast cancer patients.

Original languageEnglish
Pages (from-to)939-948
Number of pages10
JournalAnti-Cancer Drugs
Volume13
Issue number9
DOIs
StatePublished - Oct 1 2002

Fingerprint

Inbred F344 Rats
Tamoxifen
Body Weight
Uterus
Sprague Dawley Rats
Estrogen Receptor Modulators
Endometrial Neoplasms
Rodentia
Estrogens
Epithelial Cells
Breast Neoplasms
Vagina
Therapeutics
Cytoplasmic and Nuclear Receptors
Northern Blotting
Estradiol
Western Blotting
Weights and Measures

Keywords

  • Estradiol
  • Estrogen receptor
  • Rat strain
  • Tamoxifen
  • Uterus

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Strain differences in tamoxifen sensitivity of Sprague-Dawley and Fischer 344 rats. / Bailey, Jason A.; Nephew, Kenneth.

In: Anti-Cancer Drugs, Vol. 13, No. 9, 01.10.2002, p. 939-948.

Research output: Contribution to journalArticle

@article{5cd7002acab540d38f471ecf3d1aaa13,
title = "Strain differences in tamoxifen sensitivity of Sprague-Dawley and Fischer 344 rats",
abstract = "Why some women are at increased risk for the development of endometrial carcinoma while taking the antiestrogen tamoxifen (Tam) for breast cancer treatment or prevention is unknown. Various strains of rodents display differences in sensitivity to compounds with estrogenic activity, but whether differences in Tam sensitivity exist in rodent strains has not been investigated. In the present study, we investigated whether rat strain differences in reproductive tract sensitivity to Tam and estrogen exist between Fischer 344 (F344) and Sprague Dawley (SD) rats. Immature (21-23 day; n=6/group), ovariectomized F344 and SD rats were treated with vehicle (control), 17 β-estradiol (E2) [1 × 10-6 to 1.0 μg/kg body weight (BW)] or 4-OH tamoxifen (4-OHT) (1 × 10-4 to 10 mg/kg BW) for 2 days and then sacrificed on day 3. Reproductive tracts were collected, weighed, and examined for changes in histomorphology and expression of ERα and nuclear receptor co-regulators (SRC1, p300, CARM1, GRIP1, SPA, REA and Uba3). Treatment with E2 (1 × 10-5 μg/kg BW) increased (p<0.05) uterine epithelial cell height in F344 but not SD rats, demonstrating increased sensitivity of the F344 strain to E2. Conversely, treatment with 1 × 10-3 mg/kg BW 4-OHT increased (p<0.05) uterine weight and epithelial cell height in SD but not F344 rats, demonstrating that the SD strain is more sensitive to the antiestrogen. Northern and Western blot and immunohistochemical analysis revealed that ERα expression levels in the SD and F344 uterus were not different. Expression of receptor co-regulators was higher in the uterus compared to the vagina regardless of strain and higher CARM1 expression was seen in SD uterus compared to F344 rats. Understanding differences in Tam sensitivity may help us to better understand why some women develop endometrial cancer while taking Tam and be beneficial in treatment decisions for breast cancer patients.",
keywords = "Estradiol, Estrogen receptor, Rat strain, Tamoxifen, Uterus",
author = "Bailey, {Jason A.} and Kenneth Nephew",
year = "2002",
month = "10",
day = "1",
doi = "10.1097/00001813-200210000-00006",
language = "English",
volume = "13",
pages = "939--948",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Strain differences in tamoxifen sensitivity of Sprague-Dawley and Fischer 344 rats

AU - Bailey, Jason A.

AU - Nephew, Kenneth

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Why some women are at increased risk for the development of endometrial carcinoma while taking the antiestrogen tamoxifen (Tam) for breast cancer treatment or prevention is unknown. Various strains of rodents display differences in sensitivity to compounds with estrogenic activity, but whether differences in Tam sensitivity exist in rodent strains has not been investigated. In the present study, we investigated whether rat strain differences in reproductive tract sensitivity to Tam and estrogen exist between Fischer 344 (F344) and Sprague Dawley (SD) rats. Immature (21-23 day; n=6/group), ovariectomized F344 and SD rats were treated with vehicle (control), 17 β-estradiol (E2) [1 × 10-6 to 1.0 μg/kg body weight (BW)] or 4-OH tamoxifen (4-OHT) (1 × 10-4 to 10 mg/kg BW) for 2 days and then sacrificed on day 3. Reproductive tracts were collected, weighed, and examined for changes in histomorphology and expression of ERα and nuclear receptor co-regulators (SRC1, p300, CARM1, GRIP1, SPA, REA and Uba3). Treatment with E2 (1 × 10-5 μg/kg BW) increased (p<0.05) uterine epithelial cell height in F344 but not SD rats, demonstrating increased sensitivity of the F344 strain to E2. Conversely, treatment with 1 × 10-3 mg/kg BW 4-OHT increased (p<0.05) uterine weight and epithelial cell height in SD but not F344 rats, demonstrating that the SD strain is more sensitive to the antiestrogen. Northern and Western blot and immunohistochemical analysis revealed that ERα expression levels in the SD and F344 uterus were not different. Expression of receptor co-regulators was higher in the uterus compared to the vagina regardless of strain and higher CARM1 expression was seen in SD uterus compared to F344 rats. Understanding differences in Tam sensitivity may help us to better understand why some women develop endometrial cancer while taking Tam and be beneficial in treatment decisions for breast cancer patients.

AB - Why some women are at increased risk for the development of endometrial carcinoma while taking the antiestrogen tamoxifen (Tam) for breast cancer treatment or prevention is unknown. Various strains of rodents display differences in sensitivity to compounds with estrogenic activity, but whether differences in Tam sensitivity exist in rodent strains has not been investigated. In the present study, we investigated whether rat strain differences in reproductive tract sensitivity to Tam and estrogen exist between Fischer 344 (F344) and Sprague Dawley (SD) rats. Immature (21-23 day; n=6/group), ovariectomized F344 and SD rats were treated with vehicle (control), 17 β-estradiol (E2) [1 × 10-6 to 1.0 μg/kg body weight (BW)] or 4-OH tamoxifen (4-OHT) (1 × 10-4 to 10 mg/kg BW) for 2 days and then sacrificed on day 3. Reproductive tracts were collected, weighed, and examined for changes in histomorphology and expression of ERα and nuclear receptor co-regulators (SRC1, p300, CARM1, GRIP1, SPA, REA and Uba3). Treatment with E2 (1 × 10-5 μg/kg BW) increased (p<0.05) uterine epithelial cell height in F344 but not SD rats, demonstrating increased sensitivity of the F344 strain to E2. Conversely, treatment with 1 × 10-3 mg/kg BW 4-OHT increased (p<0.05) uterine weight and epithelial cell height in SD but not F344 rats, demonstrating that the SD strain is more sensitive to the antiestrogen. Northern and Western blot and immunohistochemical analysis revealed that ERα expression levels in the SD and F344 uterus were not different. Expression of receptor co-regulators was higher in the uterus compared to the vagina regardless of strain and higher CARM1 expression was seen in SD uterus compared to F344 rats. Understanding differences in Tam sensitivity may help us to better understand why some women develop endometrial cancer while taking Tam and be beneficial in treatment decisions for breast cancer patients.

KW - Estradiol

KW - Estrogen receptor

KW - Rat strain

KW - Tamoxifen

KW - Uterus

UR - http://www.scopus.com/inward/record.url?scp=0036813366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036813366&partnerID=8YFLogxK

U2 - 10.1097/00001813-200210000-00006

DO - 10.1097/00001813-200210000-00006

M3 - Article

C2 - 12394257

AN - SCOPUS:0036813366

VL - 13

SP - 939

EP - 948

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 9

ER -